US bill to shield drug companies from product liability
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7482.62-a (Published 06 January 2005) Cite this as: BMJ 2005;330:62- Jeanne Lenzer
- New York
US federal legislation that could shield drug companies from product liability lawsuits will be reintroduced in the Senate within two months, says Jack Finn, spokesperson for Senator John Ensign of Nevada state.
Senator Ensign sponsored an earlier version of the planned bill (S11) that would prohibit product liability awards for drugs or medical devices that “comply with Food and Drug Administration standards.”
The provision, known as the “FDA compliance” or “pre-emption” defence, does not apply if FDA officials were bribed or if the manufacturer withheld information about product safety.
Proponents of the legislation say that …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.